Phathom Pharmaceuticals, Inc. — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone fourth-quarter earnings report; quarterly financial results are not clearly provided in the filing text. Amounts below are in U.S. dollars.
Business context
Phathom is a development-stage biopharmaceutical company focused on gastrointestinal diseases and relies on vonoprazan, which it licensed from Takeda for the U.S., Europe, and Canada. The FDA approved VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for adult H. pylori infection in May 2022, but neither had launched by year-end. The company had no product revenue in 2022. Its NDA for VOQUEZNA for erosive GERD remained unapproved.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $71.4 million | $72.3 million |
| General and administrative expense | $101.0 million | $62.7 million |
| Total operating expenses | $172.4 million | $135.1 million |
| Net loss | $197.7 million | $143.9 million |
| Net loss per share, basic and diluted | $5.05 | $3.89 |
| Cash used in operating activities | $146.5 million | $148.5 million |
Margins are not meaningful because the company had no revenue. The net loss widened by $53.8 million. General and administrative expense rose $38.3 million, principally from commercial, medical-affairs, professional-service, and personnel costs; research and development expense declined slightly. Interest expense increased to $27.3 million from $6.8 million, including expense on the revenue-interest financing.
At December 31, 2022, cash and cash equivalents were $155.4 million, versus $183.3 million a year earlier. Total assets were $164.8 million; total liabilities were $239.6 million, including $95.3 million of long-term debt net of discount and a $109.5 million revenue-interest financing liability. Stockholders’ equity was negative $74.8 million, and accumulated deficit was $727.1 million.
Financing cash inflows in 2022 were $120.0 million: $95.4 million net proceeds from the revenue-interest financing and $24.6 million net proceeds from ATM share sales. The company reported $146.5 million of operating cash use. Management said existing cash and the remaining $100 million available under its Hercules loan were expected to fund at least 12 months; receipt of $175 million of additional financing milestones, contingent on erosive-GERD FDA approval, was expected to extend funding through 2024. These estimates depend on assumptions and contingencies.
Material developments, outlook, and risks
- Nitrosamine issue: Testing found trace N-nitroso-vonoprazan (NVP) in intended commercial product. The FDA set an acceptable daily intake of 96 ng/day and requested stability data showing levels remain at or below that limit throughout shelf life. In February 2023, the FDA issued complete response letters for the erosive-GERD NDA and a post-approval supplement for the H. pylori products. The company reported no other deficiencies in those letters. The products remained unlaunched, and GERD approval remained delayed pending resolution.
- Development: In January 2023, the company reported positive topline results for the primary endpoint in the Phase 3 daily non-erosive GERD study; full results were expected in the second half of 2023. It also planned discussions with the FDA on a Phase 3 study of as-needed dosing. These are post-year-end developments disclosed in the filing, not 2022 results.
- Clinical evidence: In the erosive-GERD Phase 3 trial, vonoprazan met the primary healing and maintenance non-inferiority endpoints and showed certain secondary superiority results. In the H. pylori trial, both vonoprazan regimens met primary non-inferiority endpoints; triple and dual therapy also showed superiority to the comparator on specified secondary analyses, including in clarithromycin-resistant patients.
- Capital obligations: Hercules debt carries variable cash interest plus 3.35% payment-in-kind interest, has a stated October 2026 maturity, and is secured by substantially all company assets, including intellectual property. The revenue-interest financing provides investors a 10% royalty on vonoprazan net sales, subject to terms including a 200% aggregate-payment cap and potential minimum payments. The Takeda license also provides for sales milestones of up to $250 million and tiered royalties.
- Execution and market risks: The business depends on one licensed drug, third-party manufacturing, successful FDA resubmissions, adequate financing, commercial launch and market uptake. Competition includes generic PPIs and other developing acid-suppression therapies; payer coverage, reimbursement, and pricing are uncertain. The company reported no material legal proceedings.
- Audit and controls: Ernst & Young issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the filing did not include an auditor attestation on internal controls because of the emerging-growth-company exemption.
Investor facts to verify
- Whether subsequent FDA submissions resolve NVP stability and shelf-life requirements, and when the H. pylori products can launch and the erosive-GERD NDA can be approved.
- Actual cash burn, financing availability, Hercules covenant compliance, and whether the contingent $175 million milestone financing is received.
- Final PHALCON-NERD-301 results, any FDA-agreed Phase 3 design for as-needed dosing, and associated costs and timelines.
- Commercial coverage, reimbursement, pricing, and adoption, along with the effect of Takeda royalties and the revenue-interest financing on future cash flows.
- Manufacturing capacity and quality oversight across Takeda, Catalent, Evonik, and Sandoz, including progress toward reliable commercial supply.
- Share dilution: 41.47 million common shares were outstanding at year-end; subsequent to year-end, the company disclosed 1.51 million ATM shares sold for $14.1 million net proceeds through February 27, 2023.